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Background: Esophageal cancer was a vital cause of cancer-related mortality worldwide, and the insulin-like
growth factor-binding proteins (IGFBPs) has been proved to be an important factor of multiple types of tumors.
There is a controversy that whether the IGFBP-3 level is associated with the clinical pathological characteristics and
overall survival of esophageal cancer patients. Herein, we aimed to comprehensively assess the association between
the low IGFBP-3 level and the risk, overall survival and clinical pathological characteristics of esophageal cancer.
Method: We conducted a meta-analysis using seven eligible studies. The overall odds ratios (OR)/relative risk (RR)
and their corresponding 95% confidence interval (CI) were calculated for each parameter.
Results: For the risk of esophageal cancer, the OR was 2.342 (p = 0.000), indicating that individuals with lower
IGFBP-3 level were more likely to suffer from esophageal cancer, compared to those with relatively high IGFBP-3
level. With respect to the 3-year survival rate, the RR was 2.163 (p = 0.027), which demonstrated that esophageal
cancer patients with low IGFBP-3 level had significantly lower 3-year survival rate; in terms of clinical pathological
characteristics, significantly lower IGFBP-3 level was found for patients in all categories; for survival status, patients in
low IGFBP-3 level are more likely to be in the dead survival status (OR = 4.480, p = 0.000).
Conclusion: Our meta-analysis suggests that for esophageal cancer, the low IGFBP-3 level is associated with high
cancer risk, poor prognosis, and unfavorable tumor stage and metastasis.
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Esophageal cancer is listed as the sixth most common
cause of cancer-related mortality worldwide, with an
estimated 456000 new cases annually in the world [1, 2].
Several factors have been reported associated with esopha-
geal cancer risk such as drinking high-temperature be-
verages, poor nutritional status, and insufficient intake of
vegetables and fruit [3–7]. Due to the asymptomatic
nature and the lack of effective approaches for early detec-
tion, individuals with esophageal cancer are usually diag-
nosed with relatively advanced stage, which contributes to
limited treatment methods available and poor prognosis* Correspondence: fenggangncch@163.com
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(http://creativecommons.org/publicdomain/ze[1, 8]. In spite of the new progress in surgery and chemo-
radiotherapy for esophageal cancer, the 5-year survival
rate is still lower than 30% [9, 10].
The insulin-like growth factor-binding proteins
(IGFBPs), together with interacting ligands and recep-
tors, comprise the insulin-like growth factor (IGF)
system [11]. IGFBP-3, which is a multifunctional protein,
is secreted by many cell types [12]. As a predominantly
secreted protein, IGFBP-3 plays important roles in sev-
eral molecular mechanisms and signaling pathways that
regulate cell survival or apoptosis, particularly in the
case of tumor [13]. It has been documented that the epi-
genetic alteration of IGFBP-3 can impact on multiple
types of tumors including non-small-cell lung cancer,
hepatocellular carcinoma, ovarian cancer, skin cancer,
urological cancers, breast cancer, and gastric cancer [14].
As for esophageal cancer, a previous study, aimed to ex-
plore the clinical and prognostic significance of IGFBP-3le is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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the clinical pathological classifications and poor overall
survival were associated with the low IGFBP-3 level [15].
Whereas, study from Sohda et al. demonstrated that no
correlation was observed between the serum IGFBP-3
level and clinical pathological features and overall survival
for esophageal cancer patients [16]. Herein, we conducted
a meta-analysis to comprehensively evaluate the associ-
ation between the low IGFBP-3 level and the risk, overall




We conducted a computer-aided literature search of
multiple databases including PubMed, EMBASE, Web of
science, Springerlink, and ProQuest. The search strategy
was the combination of Medical Subject Headings
(MeSH) and items such as esophageal cancer, carcinoma
of esophagus, esophageal carcinoma, esophagus cancer,
oesophageal carcinoma, and insulin-like growth factor
binding protein-3, IGFBP-3, IGFBP-III , IBP3, BP-53,
IBP-3, IGF-binding protein 3, IGFBP-3, acid stable sub-
unit of the 140 K IGF complex, binding protein 29, bind-
ing protein 53, growth hormone-dependent binding
protein. The last retrieval date was October 1, 2016. We
also scanned relevant reviews and reference lists of pri-
mary identified literatures to avoid any omission of eli-
gible articles.
Inclusion and exclusion criteria
In order to get reliable estimations, the following strict
inclusion criteria were defined in advance: (1) patients in
case group were diagnosed as esophageal cancer; (2)
studies focused on the expression level of IGFBP-3 be-
tween people with and without esophageal cancer; (3)
studies regarding to the correlation of IGFBP-3 with
clinical characteristics and the survival rate of patients
with esophageal cancer, regardless of the sample size
and follow-up period; (4) the IGFBP-3 expression level
was evaluated by immunohistochemical staining (IHC),
enzyme-linked immunosorbent assay (ELISA), flow cy-
tometry (FCM), or reverse transcription-polymerase chain
reaction (RT-PCR) approaches. The exclusion criteria
were as follows: (1) duplicated studies; (2) studies in which
the relevant information was unavailable; (3) some article
types such as reviews, meetings, letters, personal commu-
nications, comments, and abstracts.
Data extraction
Two independent reviewers conducted the assessment of
eligible literatures based on the above inclusion and exclu-
sion criteria. From the enrolled studies, the following in-
formation was collected: first author, year of publication,country of origin, number of participants in case/control
group, treatment before study, detection approaches for
IGFBP-3 level, median age, median follow-up period, cut-
off value of IGFBP-3 level, positivity rate, the relationship
between the expression level of IGFPB-3, and the risk and
prognosis of esophageal cancer; approaches of adjuvant
therapy, and prognostic analysis.
Statistical analysis
In our study, the clinical pathological characteristics in-
clude the age and gender of patients, the tumor location
and size, the tumor category (T, N, M, and TNM categor-
ies defined as the previous relevant studies [15, 17–19]),
and survival status (dead or alive). The overall survival is
measured by the 3-year survival rate. If the information
for overall survival is in the form of figure, we used
Engauge Digitizer version 4.1 (free software down-loaded
from http://sourceforge.net) to read the Kaplan-Meier
curves for extracting relevant data to calculate the 3-year
survival rate. The STATA 12 software (STATA Corp LP,
College Station, Texas, United States) was adopted to con-
structed forest plots, which are graphical forms to exhibit
the relative strength of effects in multiple quantitative
studies that deliver the same question. We estimated the
heterogeneity across included studies using the I2 index. If
the heterogeneity was small (I2 < 50%), the Mantel–Haens-
zel fixed-effects model was used to calculate the OR or RR
with 95% CI. Otherwise, we applied the DerSimonian and
Laird (D-L) random-effects model for the calculation of
the OR or RR with 95% CI. We used Begg’s funnel plot to
illustrate whether there was any indication of publication
bias, and when the funnel plot was asymmetric, significant
publication bias was considered. The Egger’s test was also
introduced to examine the publication bias and p < 0.05
was regarded as significant publication bias.
For cancer risk, the OR > 1 signifies that the low
IGFBP-3 level is associated with esophageal cancer, and
individuals with low IGFBP-3 level are at high-risk of
esophageal cancer. In terms of the 3-year survival rate,
the RR > 1 indicates that for patients with esophageal
cancer, the low IGFBP-3 level is associated with low 3-
year survival rate. With respect to the clinical patho-
logical features, the OR > 1 suggests that for patients
with esophageal cancer, the low IGFBP-3 level is corre-
lated with the age (patients over 60 years old are more
likely to have low IGFBP-3 level), gender (female pa-
tients are more likely to have low IGFBP-3 level), tumor
location (patients with thoracic tumor location are more
likely to have low IGFBP-3 level), tumor size (patients
with tumor size less than 6 mm are more likely to have
low IGFBP-3 level), tumor category (patients whose
tumor cells have regional lymph nodes in N category,
metastasize to distant organs in M category, and whose
tumors have extended invasion in other organs in T
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more likely to have low IGFBP-3 level), and survival sta-
tus (patients whose survival status are dead are more
likely to have low IGFBP-3 level) of patients. The signifi-
cance level was set to 0.05.
Results
Study characteristics
With the search strategy, we firstly retrieved 68 articles
from PUBMED, 57 from EMBASE, 28 from Web of sci-
ence, 132 from ProQuest, and 183 from Springerlink.
We then removed duplications, leaving 385 articles for
further assessment. After reading titles and abstracts,
357 articles were eliminated. Eventually, a total of 7 arti-
cles [15–17, 20–23] were eligible for our meta-analysis
according to our inclusion and exclusion criteria. Fig-
ure 1 showed the flow diagram of study selection and
elimination progress. All included articles were pub-
lished from 2004 to 2016, and their characteristics were
displayed in Table 1.
Evaluation of the association between the low IGFBP-3
level and the risk of esophageal cancer
There were four eligible studies for the analysis of the cor-
relation between the low IGFBP-3 level and the risk of
esophageal cancer. The results were shown in Table 2.
The fixed-effects model was used for the calculation of
OR and 95% CI, since no significant heterogeneity existedFig. 1 Flow chart of study selection and specific reasons for exclusion from(I2 = 38.8%). The OR was 2.342 (95% CI: 1.655–3.313,
Fig. 2), and significant difference (p = 0.000) was observed
in the rate of participants with low IGFBP-3 level between
patients with lung cancer and healthy subjects, which sug-
gested the low IGFBP-3 level was associated with high risk
of esophageal cancer, and individuals with low IGFBP-3
level were at high risk of esophageal cancer.
Evaluation of the association between the low IGFBP-3
level and the 3-year survival rate of esophageal cancer
As for the overall survival with the 3-year survival rate as
the endpoint, four studies were enrolled into the analysis
and the results were displayed in Table 2. Considering the
large heterogeneity (I2 = 71.2%), the random-effects model
was selected to calculate the RR and its correspond-
ing 95% CI. The RR (RR = 2.163, 95% CI: 1.092–4.287,
Fig. 3) was higher than one and the p was lower than
0.05 (p = 0.027), indicating that the low IGFBP-3 level
was associated with low 3-year survival rate, and for
esophageal cancer patients, the 3-year survival rate of pa-
tients with low IGFBP-3 level was lower than that in pa-
tients with relatively high IGFBP-3 level.
Evaluation of the association between the low IGFBP-3 level
and clinical pathological characteristics of esophageal
cancer
With respect to clinical pathological characteristics, the
results were displayed in Table 2. Although the ORs forthe mete-analysis

























Turkey 40/40 No ELISA – – Low – – –
E. Di Martino
(2006) [20]
UK 39/38 No IHC/RT-PCR 0 76.92% High Surgery – –
Lei Zhao (2012)
[15]















China 264/132 – IHC – – Low – – –
– not related in the article
aNo had not undergone surgical intervention, chemotherapy, or radiotherapy
bResults 1 the relationship between the expression level of IGFPB-3 and esophageal cancer. High high expression level of IGFPB-3 was found to be associated with
a risk of EC. Low low expression level of IGFPB-3 was found to be associated with a risk of EC
cResults 2: the relationship between IGFBP-3 and prognosis. High a high expression level of IGFPB-3 was found to be associated with improved survival rate of EC.
Low a low expression level of IGFPB-3 was found to be associated with improved survival rate of EC. No no significant association was observed between the
IGFBP-3 level and prognosis
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0.980, 95% CI: 0.520–1.860; gender: OR = 1.250, 95% CI:
0.630–2.480; location: OR = 1.145, 95% CI: 0.568–2.307;
tumor size: OR = 1.650, 95% CI: 0.900–3.010) were
higher than 1, all their corresponding p were higher than
0.05, which demonstrated that for esophageal cancer
patients, no significant association was detected between
the low IGFBP-3 level and the age, gender, tumor
location, tumor size of patients. For survival status, the
OR was 4.490 (95% CI: 2.207–9.093, p = 0.000, Fig. 4),
signifying that the low IGFBP-3 level was correlated with
the survival status of patients, and esophageal cancerTable 2 Meta-analysis of IGFBP-3 expressions for esophageal cancer
Groups I2 Pa (heterogeneity) OR Lo
Cancer risk 38.8% 0.179 2.342 1.6
3-year survival rate 71.20% 0.015 2.163* 1.0
Age 77.40% 0.035 0.980 0.5
Gender 4.70% 0.306 1.250 0.6
Location 0.00% 0.962 1.145 0.5
Tumor size 72.40% 0.057 1.650 0.9
T category 19.60% 0.265 2.870 1.5
N category 0.00% 0.863 3.211 1.5
M category 0.00% 0.380 3.270 1.6
TNM stage 0.00% 0.621 4.110 1.8
Survival status 0.00% 0.861 4.490 2.2
* value of RR
– unavailable
aThe P value for heterogeneity
bThe P value for ORpatients with low IGFBP-3 level occupied a lower sur-
vival rate.
In terms of the cancer category, we applied the fixed-
effects model for the calculation of OR and 95% CI due
to the low heterogeneity, and the results were shown in
Table 2. For patients in T category, the OR was 2.870
(95% CI: 1.510–5.450, p = 0.005, Fig. 4), implying that for
esophageal cancer patients in T category, patients whose
tumors extended invasion in other organs had lower
IGFBP-3 level than those without invasion in other
organs. For patients in N category, the OR was 3.211
(95% CI: 1.561–6.607, p = 0.002, Fig. 4), indicating thatwer limit Upper limit Pb (OR) Begg’s test Egger’s test
55 3.313 0.000 0.734 0.434
92 4.287 0.027 0.734 0.814
20 1.860 0.733 1.000 –
30 2.480 0.548 1.000 –
68 2.307 0.705 1.000 –
00 3.010 0.536 1.000 –
10 5.450 0.005 1.000 –
61 6.607 0.002 1.000 –
70 6.400 0.001 1.000 –
50 9.160 0.000 1.000 –
07 9.093 0.000 1.000 –
Fig. 2 Forest plot of study evaluating the association between the low IGFBP-3 level and the risk of esophageal cancer
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tumor cells had lymph node metastasis were signifi-
cantly lower than that in patients without lymph
nodes in tumor cells. For patients in M category, the
OR was 3.270 (95% CI: 1.670–6.400, p = 0.001, Fig. 4),
suggesting that for esophageal cancer patients in M
category, patients whose tumor cells metastasized to
distant organs (beyond regional lymph nodes) had
lower IGFBP-3 level than those without distant me-
tastases. For patients in TNM category, the OR was
4.110 (95% CI: 1.850–9.160, p = 0.000, Fig. 4), signify-
ing that for esophageal cancer patients in TNM cat-
egory, the IGFBP-3 level in patients with III–IV
tumor stage was significantly lower than that in pa-
tients with other tumor stages.Fig. 3 Forest plot of study assessing the association between the low IGFBPublication bias
Both Begg’s test and Egger’s test were used to examine
the publication bias, the results were exhibited in Table 2.
For cancer risk and 3-year survival rate, results from
both Begg’s test and Egger’s test indicated no significant
publication bias, and the corresponding funnel plots
were shown in Fig. 5a, b. With respect to other parame-
ters, it was unnecessary to construct the funnel plots
due to the small number of pooled studies, yet all the
corresponding p were higher than 0.05, inferring that
there was no significant publication bias.
Discussion
In order to comprehensively assess the correlation be-
tween low IGFBP-3 level and the risk, overall survivalP-3 level and the 3-year survival rate of esophageal cancer
Fig. 4 Forest plot of study estimating the association between the low IGFBP-3 level and clinic pathological characteristics of esophageal cancer
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cancer, we conducted the current meta-analysis incorp-
orating seven eligible studies. Our results show that for
the risk of cancer, individuals with low IGFBP-3 level are
more likely to suffer from esophageal cancer. As for the
overall survival, the esophageal cancer patients in low
IGFBP-3 level have lower 3-year survival rate than those
in relatively high IGFBP-3 level. Regarding to clinical
pathological characteristics, for T category, patients whose
tumors have extended invasion in other organs are moreFig. 5 Funnel plots for study investigating the association between the lowlikely to have low IGFBP-3 level; for N category, patients
whose tumor cells have regional lymph nodes are more
likely to have low IGFBP-3 level; for M category, patients
whose tumor cells metastasize to distant organs are more
likely to have low IGFBP-3 level; for TNM category, pa-
tients in III–IVstage are more likely to have low IGFBP-3
level; for survival status, patients in low IGFBP-3 level are
more likely to be in the dead survival status; whereas the
low IGFBP-3 level is not associated with the age, gender,
tumor location, and size of esophageal cancer patients.IGFBP-3 level and cancer risk (a) and 3-year survival rate (b)
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eighth most common cancer in the world [24]. The lack
of serosa in the esophageal wall leads to no anatomical
barrier for the spread and aggressiveness of esophageal
cancer, which contributes to the rapid extension into the
adjacent structures such as the neck, larynx, aorta, thy-
roid gland, lung, and so on [25]. Esophageal cancer can
spread by not only directly extending but also lymphatic
spread and hematogenous metastasis [25]. The manage-
ment of esophageal cancer largely depends on the pre-
operative assessment, and the standardized techniques
of assessment include upper endoscopy, high-resolution
contrast computed tomography (CT) scan, 18 fluoro-2-
deoxyglucose positron emission tomography (FDG-PET)
scan, and endoscopic ultrasonography (EUS) [26].
IGFBPs include IGF high-affinity-binding proteins
(IGFBP1-6) and IGF low-affinity IGFBP-related proteins
(IGFBP-rP1-10) [27], which prolong the half-life of IGF1
in circulation, and regulate the access of IGF1 to its recep-
tor by carrying circulating IGF1 peptide and interacting
with other proteins such as matrix metalloproteinases
(MMPs) [28]. IGFBP-3, the most abundant circulating
IGFBP, is a critical regulatory molecule of IGF system [12,
29]. The abnormal expression or dysfunction have been
associated with a verity of tumors [29]. Through both
IGF-dependent and IGF-independent pathways, IGFBP-3
possesses anti-proliferative, pro-apoptotic functions [30].
It was suggested that Smad3-P27/P21-cyclin E1/CDK2-
phosphorylated retinoblastoma protein pathways might be
involved in IGFBP-3-mediated radiosensitivity transition
in esophageal squamous cell carcinoma (ESCC) the most
prevalent histologic type of esophageal cancer in China
and eastern countries. A study of 500 ESCC patients indi-
cated that IGFBP-3 SNP rs2270628 may be associated
with ESCC in the Chinese Han population [31]. The levels
of IGFBP-3 protein expression in ESCC tissues were de-
creased [32]. In addition, Yilmaz et al. performed a case-
control study and observed that the level of IGFBP-3 was
related with esophageal cancer risk and patients with
esophageal cancer had significantly lower IGFBP-3 levels,
compared with the control group (healthy people) [21].
Our study also revealed that the IGFBP-3 level in patients
with esophageal cancer was significantly lower than that
in healthy participants.
Overall survival (OS), an easily appreciated parameter,
remains the strongest trial endpoint in cancer clinical
trials, which is independent of bias resulting from the
definition of progression, approaches of evaluation, and
clinical assessment [33]. Previous studies implied that
for esophageal cancer patients, the elevated IGFPB-3
level was significantly associated with improved overall
survival [15, 17], which was inconsistent with the related
study published in 2004 [16]. However, with large sam-
ple size by pooling relevant data together, our meta-analysis indicated that low IGFPB-3 level was predictive
for poor overall survival for esophageal cancer patients.
Furthermore, significant association was observed be-
tween the low IGFBP-3 level and clinical pathological
characteristics including the tumor category and survival
status rather than the age, gender, tumor location, and
tumor size of patients in current meta-analysis.
Serum human relaxin 2, which impacts on the remodel-
ing of several tissue components including matrix metal-
loproteinase, extracellular matrix, and collagen, has been
discovered as a potential prognostic factor for esophageal
cancer, and patients with higher human relaxin 2 level had
shorter survival period, more distant metastasis and
higher tumor stage [25]. A previous meta-analysis demon-
strated that the high level of serum C-reactive protein
were significantly correlated with poor overall survival in
esophageal cancer patients [34]. The identification of
matrix metalloproteinase-7 protein was also proved as a
promising biomarker for esophageal cancer progression
[35]. Our study revealed that the IGFBP-3 was another
potential diagnostic and prognostic biomarker for esopha-
geal cancer.
The present study is the first meta-analysis to assess
the association between the low IGFBP-3 level and the
risk, overall survival, and clinical pathological character-
istics of esophageal cancer. However, some limitations
exist in the current study. Firstly, the test methods of
IGFBP-3 level were not exactly the same in the six in-
cluded studies, and with more relevant studies becoming
available, subgroup analysis stratified by different detec-
tion methods of IGFBP-3 level should be made for a
more reliable estimation. Secondly, the cut-off value of
IGFBP-3 level for the determination of esophageal can-
cer was not quite the same, which might result in some
bias for our meta-analysis. Additionally, the unpublished
articles were not retrieved in our study.Conclusion
The current meta-analysis suggests that the lower IGFBP-
3 level is significantly associated with higher cancer risk,
lower 3-year survival rate, more advanced tumor stages,
and more distant metastasis. The low IGFBP-3 level is a
promising predictor for high-risk, poor prognosis, and un-
favorable tumor stage and metastasis of esophageal
cancer.Abbreviations
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immunosorbent assay; EUS: Endoscopic ultrasonography; FCM: Flow
cytometry; FDG-PET: 18 fluoro-2-deoxyglucose positron emission
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PCR: Reverse transcription-polymerase chain reaction
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